Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Unicycive Therapeutics, Inc.(UNCY) Shareholders

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2] - It is also alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were exaggerated [2] - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]